EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma

Massimo Martino iD, Violetta Marafioti, Martina Pitea iD, Gaetana Porto iD, Giorgia Policastro, Filippo Antonio Canale, Virginia Naso, Caterina Alati

Cancers · 05.08.2026 · 18 (15) · 2513

DOI: 10.3390/cancers18152513 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.08.2026. Verfasst von Massimo Martino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropol…. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment paradigm for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) has undergone significant change with the advent of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies and CD20 × CD3 bispecific antibodies (BsAbs). Although both approaches have shown high response rates in single-arm studies, the absence of prospective randomized head-to-head comparisons has resulted in true clinical equipoise.

Methods

A narrative synthesis was conducted, incorporating pivotal and updated phase 2 and 3 trial data, real-world evidence, and published meta-analyses.

Results

In the second-line setting, CAR-T therapy demonstrates superior event-free survival, progression-free survival, and overall survival compared to standard-of-care chemo-transplant regimens. In the third-line setting, a pooled meta-analysis indicates significantly higher complete response rates for CAR-T compared with BsAbs, as well as superior 12-month progression-free survival. BsAbs provide immediate availability, greater accessibility, more favorable neurotoxicity profiles, and are feasible for frail or elderly patients. Real-world data show that BsAb complete response rates are consistently lower than those observed in clinical trials, whereas CAR-T real-world effectiveness closely aligns with pivotal trial outcomes. Emerging phase 3 data on fixed-duration and monotherapy bispecific regimens suggest that a genuine, if less mature, curative fraction may also be achievable among BsAb-treated complete responders.

Conclusions

CAR-T therapy remains the standard of care for fit, eligible patients with R/R LBCL in second- and third-line settings with curative intent, providing superior depth and durability of response and a growing potential for long-term cure. BsAbs constitute a critical therapeutic alternative for patients ineligible for CAR-T, those with rapidly progressive disease, frail or elderly individuals, and as bridging strategies. A patient-centered, scenario-specific clinical decision framework is recommended.

Schlagwörter

Stichwörter der Autor:innen

CAR-T-cell therapyaxicabtagene ciloleucelbispecific antibodiesdiffuse large B-cell lymphomaepcoritamabglofitamablisocabtagene maraleucelrelapsed/refractory lymphomasecond-line therapythird-line therapy

Autor:innen und Institutionen

  • Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.

ORCID-Profile: Massimo Martino, Martina Pitea, Gaetana Porto

Zitieren

APA

Martino, M., Marafioti, V., Pitea, M., Porto, G., Policastro, G., Canale, F. A., Naso, V., & Alati, C. (2026). The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma. Cancers, 18(15), 2513. https://doi.org/10.3390/cancers18152513

Vancouver

Martino M, Marafioti V, Pitea M, Porto G, Policastro G, Canale FA, et al. The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma. Cancers. 2026;18(15):2513. doi:10.3390/cancers18152513

BibTeX
@article{Martino2026,
  author = {Martino, Massimo and Marafioti, Violetta and Pitea, Martina and Porto, Gaetana and Policastro, Giorgia and Canale, Filippo Antonio and Naso, Virginia and Alati, Caterina},
  title = {The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2513},
  doi = {10.3390/cancers18152513}
}
Kostenlos starten →